International Journal of Cardiovascular ResearchISSN: 2324-8602

Reach Us +1 850 900 2634

Research Article, Int J Cardiovasc Res Vol: 2 Issue: 2

The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine

David Jang1*, Sean Donovan2, Theodore Bania2, Lewis Nelson3, Robert Hoffman3 and Jason Chu4
1New York University School of Medicine, USA
2Department of Emergency Medicine St. Luke’s-Roosevelt Hospital Center, USA
3Department of Emergency Medicine New York University School of Medicine Bellevue Hospital Center New York, New York, USA
Corresponding author : David Jang
Assistant Professor, New York University School of Medicine, USA
E-mail: [email protected]
Received: February 28, 2013 Accepted: March 04, 2013 Published: March 29, 2013
Citation: Jang D, Donovan S, Bania T, Nelson L, Hoffman R, et al. (2013) The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. Int J Cardiovasc Res 2:2. doi:10.4172/2324-8602.1000121

Abstract

The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine

Cardiovascular drug poisoning remains a leading cause of fatality. Within this class, calcium channel blockers(CCBs) account for the majority of deaths. CCBs are typically categorized as dihydropyridines (i.e. amlodipine or nifedipine) versus the non-dihydropyridine (i.e. verapamil and diltiazem) which are the most potent and once considered the CCB type responsible for all CCB-related deaths. Most recently, dihydropyridine deaths have increased. While there are established models of nondihydropyridine poisoning there currently are no established experimental models of dihydropyridine poisoning.

Keywords: Cardiovascular drug; LD50; Dihydropyridine

Track Your Manuscript

Share This Page

Media Partners